Lanthanum carbonate

Drug Profile

Lanthanum carbonate

Alternative Names: Bay 771931; Fosrenol; Foznol; Lambda; SPD405

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Bayer Yakuhin; Shire
  • Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 30 Nov 2015 Launched for Hyperphosphataemia (Late-stage disease) in USA before November 2015 (PO)
  • 27 Apr 2015 The product is still in phase-II for Hyperphosphataemia (in children) in Germany and Hungary
  • 24 Sep 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top